Density of tumor-infiltrating FOXP3+ T cells as a response marker for induction chemoradiotherapy and a potential prognostic factor in patients treated with trimodality therapy for locally advanced non-small cell lung cancer.
暂无分享,去创建一个
J. Soh | S. Toyooka | S. Miyoshi | K. Shien | K. Okabe | E. Matsuda | H. Tao
[1] J. Matsumoto,et al. Novel aspects of preoperative chemoradiation therapy improving anti‐tumor immunity in pancreatic cancer , 2013, Cancer science.
[2] R. G. van der Most,et al. Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies , 2012, British Journal of Cancer.
[3] S. Toyooka,et al. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. , 2012, Interactive cardiovascular and thoracic surgery.
[4] P. Granone,et al. Induction therapy followed by surgery for T3-T4/N0 non-small cell lung cancer: long-term results. , 2012, The Annals of thoracic surgery.
[5] R. deLeeuw,et al. The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature , 2012, Clinical Cancer Research.
[6] P. Granone,et al. Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[7] C. Coutant,et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival , 2011, The Journal of pathology.
[8] M. Liptay,et al. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. , 2011, The Annals of thoracic surgery.
[9] G. D. de Bock,et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.
[10] R. Stahel,et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. , 2010, The Journal of thoracic and cardiovascular surgery.
[11] K. Shimizu,et al. Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] R. Fimmers,et al. Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma , 2010, Cancer Immunology, Immunotherapy.
[13] C. Dooms,et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[14] N. Kawashima,et al. Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.
[15] N. Funata,et al. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. , 2009, Oncology reports.
[16] E. Ruffini,et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. , 2009, The Annals of thoracic surgery.
[17] A. Gemma,et al. Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer , 2008, Cancer.
[18] W. Hilgers,et al. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[19] B. Chauffert,et al. Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.
[20] A. Fattorossi,et al. Neuropilin‐1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer , 2008, Immunology.
[21] T. Okamoto,et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. , 2007, The Journal of thoracic and cardiovascular surgery.
[22] Kenji Suzuki,et al. How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer , 2007, British Journal of Cancer.
[23] V. Rusch,et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] T. Oshikiri,et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma , 2006, British Journal of Cancer.
[25] K. Kiura,et al. Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer , 2004, British Journal of Cancer.
[26] N. Kawashima,et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.
[27] Koichi Yamazaki,et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non‐small cell lung cancers , 2003, Cancer science.
[28] D. Speiser,et al. Human CD8+ T cells expressing HLA‐DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells , 2001, European journal of immunology.
[29] H. Ohtani,et al. Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. , 2000, The Tohoku journal of experimental medicine.
[30] U. Pastorino,et al. Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial , 1999, British Journal of Cancer.
[31] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.